| Literature DB >> 28959563 |
Reyna Cristina Collí-Dulá1, Marvin A Friedman2, Benjamin Hansen3, Nancy D Denslow1.
Abstract
Acrylamide is known to produce follicular cell tumors of the thyroid in rats. RccHan Wistar rats were exposed in utero to a carcinogenic dose of acrylamide (3 mg/Kg bw/day) from gestation day 6 to delivery and then through their drinking water to postnatal day 35. In order to identify potential mechanisms of carcinogenesis in the thyroid glands, we used a transcriptomics approach. Thyroid glands were collected from male pups at 10 PM and female pups at 10 AM or 10 PM in order to establish whether active exposure to acrylamide influenced gene expression patterns or pathways that could be related to carcinogenesis. While all animals exposed to acrylamide showed changes in expected target pathways related to carcinogenesis such as DNA repair, DNA replication, chromosome segregation, among others; animals that were sacrificed while actively drinking acrylamide-laced water during their active period at night showed increased changes in pathways related to oxidative stress, detoxification pathways, metabolism, and activation of checkpoint pathways, among others. In addition, thyroid hormones, triiodothyronine (T3) and thyroxine (T4), were increased in acrylamide-treated rats sampled at night, but not in quiescent animals when compared to controls. The data clearly indicate that time of day for sample collection is critical to identifying molecular pathways that are altered by the exposures. These results suggest that carcinogenesis in the thyroids of acrylamide treated rats may ensue from several different mechanisms such as hormonal changes and oxidative stress and not only from direct genotoxicity, as has been assumed to date.Entities:
Keywords: ADA, adenosine Deaminase; ADRB2, adrenergic; ASF1B, anti-Silencing Function 1B Histone Chaperone; Acrylamide; BRIP1, BRCA1 Interacting Protein C-Terminal Helicase 1; BUB1B, BUB1 Mitotic Checkpoint Serine/Threonine Kinase B; C1QTNF3, C1q and Tumor Necrosis Factor Related Protein 3; C5, complement Component 5; CALCR, calcitonin receptor; CARD9, caspase recruitment domain family; CCNA2, cyclin A2; CCNG1, cyclin G1; CD45, protein tyrosine phosphatase; CD46, CD46 molecule; CDC45, cell division cycle 45; CDCA2, cell division cycle associated 2; CDCA5, cell division cycle associated 5; CENPT, centromere protein T; CFB, complement factor B; CGA, glycoprotein hormones; CTLA4, cytotoxic T-lymphocyte-associated protein 4; DAD1, defender against cell death 1; DCTPP1, DCTP pyrophosphatase 1; DNMT3A, DNA (cytosine-5-)-methyltransferase 3 alpha; DUOX2, dual oxidase 2; GCG, glucagon; GCLC, glutamate-cysteine ligase; GOLGA3, golgin A3; GSTM1, glutathione S-transferase Mu 1; GSTP1, glutathione S-transferase Pi 1; HPSE, heparanase; HSPA5, heat shock 70 kDa protein 5; HSPB1, heat shock 27 KDa protein; HSPB2, heat shock 27 kDa protein 2; HSPH1, heat shock 105 kDa/110 kDa protein 1; HTATIP2, HIV-1 tat interactive protein 2; ID1, inhibitor of DNA binding 1; IGF2, Insulin-like growth factor 2 (somatomedin A); IL1B, interleukin 1; INHBA, inhibin; IYD, iodotyrosine deiodinase; KIF20B, kinesin family member 20B; KIF22, kinesin family Member 22; KLK1, kallikrein 1; LAMA2, laminin, alpha 2; MCM8, minichromosome maintenance complex component 8; MIF, macrophage migration inhibitory factor; MIS18A, MIS18 kinetochore protein A; NDC80, NDC80 kinetochore complex component; NPPC, natriuretic peptide precursor C; NPY, neuropeptide; NUBP1, nucleotide binding protein 1; ORC1, origin recognition complex; PDE3A, phosphodiesterase 3A; PINK1, PTEN induced putative kinase 1; PLCD1, phospholipase C; PLK1, polo-like kinase 1; POMC, proopiomelanocortin; PRKAA2, protein kinase; PRL, prolactin; PRODH, proline dehydrogenase; PTGIS, prostaglandin I2 (prostacyclin) synthase; PTGS1, prostaglandin-endoperoxide synthase 1; RAB5A, RAB5A; RAN, ras-related nuclear protein; RRM2, ribonucleotide reductase M2; RccHan Wistar; SCL5A5, solute carrier family 5 (sodium iodide symporter); SELP, selectin P (granule membrane protein 140 kDa; SPAG8, sperm associated antigen 8; TACC3, transforming; TBCB, tubulin folding cofactor B; TFRC, transferrin receptor; TOP2A, topoisomerase (DNA) II alpha; TPO, thyroid peroxidase; TSHR, thyroid stimulating hormone receptor; TSN, translin; Thyroid; Transcriptomics; VWF, Von Willebrand Factor
Year: 2016 PMID: 28959563 PMCID: PMC5615912 DOI: 10.1016/j.toxrep.2016.03.009
Source DB: PubMed Journal: Toxicol Rep ISSN: 2214-7500
Genes selected for confirmation by qPCR.
| Night group genes | |||
|---|---|---|---|
| Gen bank Accession | Gene Name | Gene Symbol | ID |
| Caspase recruitment domain family, member 9 | Card9 | Rn00673582_m1 | |
| Dopamine receptor D2 | Drd2 | Rn00561126_m1 | |
| DNA-damage-inducible transcript 4 | Ddit4 | Rn01433735_g1 | |
| Thyroid peroxidase | Tpo | Rn00571159_m1 | |
| NM_001009623 | Tumor necrosis factor (ligand) superfamily, member 13 | Tnfsf13 | Rn01467490_g1 |
| Morning group gene | |||
| Aurora kinase B | Aurkb | Rn01460656_m1 | |
| Dual oxidase 2 | Duox2 | Rn01514628_m1 | |
| NM_001106335.1 | Inner centromere protein | Incenp | Rn01478880_g1 |
| Proopiomelanocortin | Pomc | Rn00595020_m1 | |
| Topoisomerase (DNA) II alpha | Top2a | Rn00573347_m1 | |
| Normalizing Gene | |||
| 45S pre-ribosomal RNA | 18S | Rn03928990_g1 | |
TaqMan assays ID (Applied Biosystems).
Fig. 1Plasma levels of thyroid hormones and TSH in animals collected in the morning and at night (n = 5 per group). (A, C, E) Animals sampled in the morning; (B, D, F) animals sampled at night with (A, B) TSH; (C, D) T3; and (E, F) T4. Box plots indicate the upper and lower percentile (10–90th) and the median values (horizontal black line within box). Whiskers represent the highest and lowest points. Different letters indicate significant differences among groups. CTRL (control group); AA (Acrylamide-treated group); MM (male morning); FM (female morning); MN (male night); FN (female night).
Fig. 2Changes in gene expression that were related to thyroid hormone generation and thyroid function in male rats sampled at night. Pathways were built by sub-networks enrichment analysis (p-value >0.05; fold change > ± 1.2; statistically analyzed by Fisher’s Exact Test) using PathwayStudio™. Blue indicates down-regulation of gene expression; red, up-regulation; and yellow indicates the processes likely affected. Color intensity correlates with the degree of response. The abbreviations of the genes are listed in the abbreviations list.
Partial list of transcripts from males and females collected at night that were most changed including those encoding processes involved with thyroid hormone generation, processing and protein transport, motor proteins, detoxifying enzymes, transcripts involved in oxidative stress, and checkpoint pathways involved in cancer.
| Probe Name | Gen bank Accession | Gene Symbol | Gene Name | Fold Change | |
|---|---|---|---|---|---|
| Male | Female | ||||
| Thyroid hormone | |||||
| A_64_P076450 | Pomc | Proopiomelanocor-tin | 18.4 | 6.3 | |
| A_64_P155193 | Dio1 | Deiodinase, iodothyronine, type I | 1.4 | 1.6 | |
| A_42_P625922 | Drd2 | Dopamine receptor | 5.2 | 2.4 | |
| A_44_P238257 | Trip10 | Thyroid hormone receptor interactor 10 | −1.5 | −1.3 | |
| Processing and protein transport | |||||
| A_43_P16457 | NM_001037208 | Creld2 | Cysteine-rich with EGF-like domains 2 | 2.2 | 2.1 |
| A_64_P056846 | Gclc | Glutamate-cysteine ligase, catalytic subunit | 2.0 | 1.4 | |
| A_64_P021433 | NM_001007755 | Scly | Selenocysteine lyase | 1.7 | 1.3 |
| Motor proteins | |||||
| A_42_P757258 | NM_001107609 | Kif20b | Kinesin family member 20B | 1.8 | 1.3 |
| A_64_P108200 | NM_001009645 | Kif22 | Kinesin family member 22 | 1.7 | 1.2 |
| A_64_P111749 | XM_001057533 | Kif2a | Kinesin family member 2A | 1.7 | 1.9 |
| A_44_P163018 | NM_001009619 | Nubp1 | Nucleotide binding Protein 1 | 1.3 | 1.2 |
| A_44_P463313 | Plk1 | polo-like kinase 1 | 1.5 | 1.3 | |
| A_44_P213149 | NM_001107369 | Mastl | Microtubule associated serine/threonine kinase-like | 2.3 | 1.6 |
| Detoxifying enzymes/Oxidative Stress | |||||
| A_64_P137037 | Cyp2b12 | Cytochrome P450, family 2, subfamily b, polypeptide 12 | 1.4 | 2.0 | |
| A_64_P004231 | NM_001159739 | Gsta5 | Glutathione S-transferase Yc2 subunit | 2.5 | 1.5 |
| A_42_P678430 | Card9 | Caspase recruitment domain family, member 9 | 1.6 | 1.4 | |
| A_64_P119916 | Duox2 | Dual oxidase 2 | 1.7 | 1.2 | |
| A_64_P095830 | Gpr56 | G protein-coupled receptor 56 | 1.6 | 1.3 | |
| A_42_P636627 | Cartpt | CART prepropeptide | 1.6 | 2.4 | |
| A_64_P069374 | Scn10a | Sodium channel, voltage-gated, type X, alpha | 3.1 | 1.9 | |
| A_64_P035564 | NM_001108682 | Tlr12 | Toll-like receptor 12 | 1.6 | 1.8 |
| Checkpoint pathways and cancer | |||||
| A_64_P012009 | NM_001106787 | Mov10L1 | Mov10L1, Moloney leukemia virus 10-like 1, homolog (mouse) | 3.2 | 2.4 |
| A_44_P478066 | NM_001106335 | Incenp | Inner centromere protein | 1.4 | 1.4 |
| A_64_P033214 | Top2a | Topoisomerase (DNA) II alpha | 1.5 | 1.5 | |
| A_43_P10723 | XM_001080736 | Bub1b | Budding uninhibited by benzimidazoles 1 homolog, beta | 1.7 | 1.4 |
| A_44_P1045354 | Slc35b1 | Solute carrier family 35, member B1 | 1.9 | 1.3 | |
Common genes significantly altered by AA in females sampled in the morning (AM) and at night (PM).
| Fold Change (p < 0.05) | |||||
|---|---|---|---|---|---|
| Probe Name | Gen bank Accession | Gene Symbol | Gene Name | AM | PM |
| A_44_P533786 | Aurkb | Aurora kinase B | 2.8 | 1.4 | |
| A_44_P461544 | NM_001009470 | Ccnb2 | Cyclin B2 | 2.8 | 1.5 |
| A_44_P534089 | Ccnb1 | Cyclin B1 | 2.7 | 1.4 | |
| A_42_P535608 | NM_001107160 | Asf1b | ASF1 anti-silencing function 1 homolog B (S. cerevisiae) | 2.6 | 1.4 |
| A_44_P189375 | NM_001001719 | Fancd2 | Fanconi anemia, complementation group D2 | 2.6 | 1.5 |
| A_44_P381917 | Sphk1 | Sphingosine kinase 1 | 2.5 | 1.7 | |
| A_44_P223446 | NM_001107873 | Mcm2 | Minichromosome maintenance complex component | 2.4 | 1.4 |
| A_44_P478066 | NM_001106335 | Incenp | Inner centromere protein | 2.3 | 1.4 |
| A_44_P213149 | NM_001107369 | Mastl | Microtubule associated serine/threonine kinase-like | 2.3 | 1.6 |
| A_64_P075910 | NM_001101014 | Ajap1 | Adherens junction associated protein 1 | 2.2 | 1.6 |
| A_64_P129618 | NM_001017459 | Mdm1 | Mdm1 nuclear protein homolog (mouse) | 2.2 | 1.2 |
| A_42_P643574 | NM_001106795 | Aaas | Achalasia, adrenocortical insufficiency, alacrimia (Allgrove, triple-A) | 1.7 | 1.2 |
| A_42_P502590 | NM_001107424 | Slc7a6 | Solute carrier family 7 (cationic amino acid transporter, y+ system), member 6 | 1.6 | 1.2 |
| A_64_P097193 | XM_001072207 | Topbp1 | Topoisomerase (DNA) II binding protein 1 | 1.5 | 1.2 |
| A_64_P008477 | NM_001000247 | Olr325 | Olfactory receptor 325 | −1.4 | −1.2 |
| A_42_P463998 | Abcc6 | ATP-binding cassette, sub-family C (CFTR/MRP), member 6 | −1.5 | −2.0 | |
| A_64_P029596 | NM_001102417 | Svs3b | Seminal vesicle secretory protein 3B | −1.6 | −3.0 |
| A_44_P302179 | XM_001070842 | Naip5 | NLR family, apoptosis inhibitory protein 5 | −1.6 | −1.4 |
| A_44_P612186 | NM_001107344 | Mylip | Myosin regulatory light chain interacting protein | −1.6 | −1.2 |
| A_44_P279116 | XM_002726450 | Dyrk4 | Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 4 | −1.6 | −1.3 |
| A_64_P083349 | Kitlg | KIT ligand | −1.6 | −1.3 | |
| A_64_P010648 | NM_001105822 | Ccl12 | Chemokine (C-C motif) ligand 12 | −1.7 | −1.4 |
| A_64_P008330 | NM_001000020 | Olr1454 | Olfactory receptor 1454 | −1.7 | −1.3 |
| A_44_P1000391 | NM_001106140 | Atp8b1 | ATPase, Class I, type 8B, member 1 | −1.8 | −1.2 |
| A_64_P050650 | Sox4 | SRY (sex determining region Y)-box 4 | −1.9 | −1.3 | |
| A_64_P127823 | NM_001108629 | Ggct | Gamma-glutamyl cyclotransferase | −1.9 | −1.2 |
| A_44_P684740 | NM_001107279 | Pcdh17 | Protocadherin 17 | −2.3 | −1.4 |
| A_64_P008502 | NM_001109574 | Tmem169 | Transmembrane protein 169 | −2.7 | −1.5 |
| A_43_P12257 | Esm1 | Endothelial cell-specific molecule 1 | −2.9 | −1.6 | |
Partial list of common sub-networks significantly affected in the thyroid gland of male and female rats exposed to AA. Complete data are shown in Table SI-2.
| Sub-networks | p-value (<0.05) | ||
|---|---|---|---|
| Gene Set Seed | Male at night | Female at night | Female at morning |
| Cell proliferation | 8.3E-14 | 1.1E-10 | 9.4E-11 |
| Cell differentiation | 2.0E-11 | 1.9E-10 | 5.4E-10 |
| Apoptosis | 3.4E-10 | 9.2E-15 | 4.1E-13 |
| Cell death | 4.9E-10 | 7.6E-09 | 1.3E-07 |
| Cell migration | 6.3E-09 | 5.7E-06 | 1.2E-06 |
| Vascularization | 2.7E-08 | 1.7E-03 | 3.2E-07 |
| Cell growth | 5.0E-08 | 2.5E-08 | 6.1E-11 |
| Cell cycle | 9.2E-08 | 6.3E-08 | 9.1E-07 |
| Pregnancy | 7.3E-07 | 3.7E-03 | 2.3E-03 |
| Oxidative stress | 7.6E-07 | 8.6E-04 | 7.9E-06 |
| Cell survival | 1.7E-06 | 5.1E-05 | 1.7E-05 |
| Endocytosis | 2.3E-06 | 5.2E-04 | 4.5E-07 |
| Heart function | 4.6E-06 | 6.3E-03 | 6.9E-03 |
| Contraction | 1.4E-05 | 2.3E-03 | 4.9E-03 |
| G2/M transition | 1.7E-05 | 1.4E-05 | 2.6E-04 |
| Morphogenesis | 2.1E-05 | 1.9E-06 | 2.4E-03 |
| Ossification | 3.6E-05 | 1.2E-04 | 1.8E-02 |
| Inflammatory response | 6.2E-05 | 4.7E-03 | 4.9E-03 |
| Protein folding | 2.6E-04 | 1.0E-03 | 1.5E-02 |
| Myogenesis | 1.4E-04 | 8.6E-04 | 4.0E-04 |
| DNA replication | 5.0E-04 | 8.9E-04 | 2.8E-03 |
| Response to hypoxia | 9.8E-04 | 8.9E-03 | 5.0E-03 |
Sub-networks that were significantly altered by AA in female rats sampled at night (FN) or in the morning (FM) (statistically tested by Fisher’s Exact Test (p < 0.05, data in order of lowest p-value).
| Gene Set Seed | p-value (FN) | p-value (FM) |
|---|---|---|
| Mitosis | 8.05E-07 | NE |
| Embryonal development | 6.85E-06 | NE |
| M phase | 4.61E-05 | NE |
| Kinetochore assembly | 5.01E-05 | NE |
| Meiosis | 7.94E-05 | NE |
| Oncogenesis | 1.13E-04 | NE |
| DNA replication checkpoint | 1.30E-04 | NE |
| Macrophage differentiation | 1.67E-04 | NE |
| G2 phase | 1.67E-04 | NE |
| Genetic instability | 1.99E-04 | NE |
| G2/M checkpoint | 2.60E-04 | NE |
| Regeneration | 2.83E-04 | NE |
| Response to stress | 3.52E-04 | NE |
| Mitotic entry | 4.76E-04 | NE |
| Mitotic checkpoint | 4.87E-04 | NE |
| Muscle development | 4.98E-04 | NE |
| Fibroblast accumulation | 5.22E-04 | NE |
| Muscle regeneration | 5.41E-04 | NE |
| ER-associated protein catabolism | 6.76E-04 | NE |
| Microtubule cytoskeleton assembly | 7.21E-04 | NE |
| Erythrocyte differentiation | 7.79E-04 | NE |
| Nerve maturation | 8.50E-04 | NE |
| Xenobiotic metabolism | 8.61E-04 | NE |
| Mitotic spindle assembly | 9.06E-04 | NE |
| Chromosome condensation | 1.03E-03 | NE |
| Cell adhesion | NE | 1.77E-05 |
| Mitochondrial damage | NE | 2.81E-05 |
| Regulation of cell size | NE | 5.23E-05 |
| Muscle cell differentiation | NE | 9.85E-05 |
| Kidney function | NE | 1.19E-04 |
| Glial cell response | NE | 1.40E-04 |
| Cell-cell adhesion | NE | 1.57E-04 |
| Adipocyte differentiation | NE | 1.61E-04 |
| Wound healing | NE | 4.84E-04 |
| SMC proliferation | NE | 5.90E-04 |
| Neuron apoptosis | NE | 6.80E-04 |
| Luteinization | NE | 8.26E-04 |
| G1 phase | NE | 8.44E-04 |
| Senescence | NE | 8.79E-04 |
| Actin organization | NE | 9.21E-04 |
| Secretory pathway | NE | 1.14E-03 |
| Endothelial cell function | NE | 1.15E-03 |
| Endothelial cell proliferation | NE | 1.22E-03 |
| Myocyte proliferation | NE | 1.26E-03 |
| Colonization | NE | 1.28E-03 |
| Arteriogenesis | NE | 1.39E-03 |
| Embryo implantation | NE | 1.40E-03 |
| Biomineral formation | NE | 1.44E-03 |
| Autophagic cell death | NE | 1.65E-03 |
| Endomitotic cell cycle | NE | 1.74E-03 |
NE; No effect.
Common pathways identified by GSEA in the thyroid gland of male and female rats exposed to AA.
| Gene Set Category: Ariadne Cell Process Pathways | Male at night | Female at night | Female at morning | |||
|---|---|---|---|---|---|---|
| Median change | p-value | Median change | p-value | Median change | p-value | |
| DNA replication | 1.3 | 0.01 | 1.1 | 0 | 1.1 | 0 |
| Histone and DNA methylation | 1.2 | 0.02 | 1.1 | 0 | NE | 0.01 |
| Histone phosphorylation | 1.1 | 0 | 1.1 | 0 | 1.1 | 0 |
| Direct DNA repair | 1.1 | 0.02 | 1.1 | 0 | 1.1 | 0.01 |
| Single-strand mismatch DNA repair | 1.2 | 0 | 1.1 | 0 | 1.1 | 0 |
| Double strand DNA homologous repair | 1.2 | 0 | 1.1 | 0 | 1.1 | 0 |
| Single-strand base excision DNA repair | 1.2 | 0.01 | 1.1 | 0 | 1.1 | 0 |
| Cell cycle | 1.2 | 0 | 1.1 | 0 | 1.1 | 0 |
| Actin cytoskeleton assembly | 1.1 | 0 | NE | 0.02 | 1.2 | 0.01 |
| Tight junction assembly (Occludin) | 1.2 | 0 | 1.1 | 0.03 | NE | 0.01 |
NE; No effect.
Fig. 3Alterations in gene expression related to (A–B) spindle assembly and (C–D) kinetochore assembly. These pathways were built using sub-networks enrichment analysis (SNEA) (p-value > 0.05; fold change >± 1.2; by Fisher’s Exact Test) using PathwayStudio™. (A, C) Male rats sampled at night; and (B, D) female rats sampled at night. Blue, down-regulated genes; red, up-regulated genes. Abbreviations for gene names are in the abbreviation list.
Fig. 4Alterations in gene expression related to reactive oxygen species (A-B) (ROS) and (C-D) microtubule cytoskeleton assembly. These pathways were built using sub-networks enrichment analysis (SNEA) (p-value > 0.05; fold change >± 1.2; by Fisher’s Exact Test) using PathwayStudio™. (A, C) Male rats sampled at night; and (B, D) female rats sampled at night. Blue, down-regulated genes; red, up-regulated genes. Abbreviations for gene names are in the abbreviation list.
Fig. 5Genes altered by AA exposure of rats that relate to (A-B) DNA replication and (C-D) DNA repair. These pathways were built using sub-networks enrichment analysis (p-value > 0.05; fold change >± 1.2; by Fisher’s Exact Test) using PathwayStudio™. (A, C) Male rats sampled at night; and (B, D) female rats sampled at night. Blue, down-regulated genes; and red, up-regulated genes. Abbreviations for gene names are in the abbreviation list.
Differences in pathways determined by GSEA in female rats sampled at night or in the morning (p < 0.05, data ordered by lowest p-value).
| Females | ||||
|---|---|---|---|---|
| Gene Set Category: | Night | Morning | ||
| Ariadne Cell Process Pathways | Median change | p-value | Median change | p-value |
| Histone and DNA methylation | 1.1 | 0 | NE | NE |
| SWI/SNF BRG1/BAF Chromatin remodeling | 1.1 | 0 | NE | NE |
| SWI/SNF BRG1/PBAF Chromatin remodeling | 1.1 | 0 | NE | NE |
| NURD Chromatin remodeling | 1.1 | 0 | NE | NE |
| NURF Chromatin remodeling | 1.1 | 0 | NE | NE |
| CHRAC Chromatin remodeling | 1.1 | 0 | NE | NE |
| SRCAP Chromatin remodeling | 1.1 | 0 | NE | NE |
| Presentation of endogenous peptide antigen | 1.1 | 0 | NE | NE |
| mRNA Transcription and processing | 1.1 | 0 | NE | NE |
| rRNA Transcription and processing | 1.1 | 0 | NE | NE |
| Histones sumoylation | 1.1 | 0 | NE | NE |
| Single-strand nucleotide excision DNA repair | 1.1 | 7.5E-03 | NE | NE |
| SWI/SNF BRM/BAF Chromatin remodeling | 1.1 | 2.0E-02 | NE | NE |
| Tight junction assembly (Occludin) | 1.1 | 2.8E-02 | NE | NE |
| Classical complement pathway | −1.2 | 4.0E-02 | NE | NE |
| Ubiquitin-dependent protein degradation | 1.1 | 4.2E-02 | 1.10 | 4.9E-03 |
| Actin cytoskeleton assembly | NE | NE | 1.15 | 1.0E-02 |
NE; No effect.
Comparison of fold changes in mRNA steady state levels obtained from microarray and qPCR analyses for selected genes involved in cell checkpoint pathways and oxidative stress for male and female rats sampled in the morning and at night.
| (A) Morning group | Female | |
|---|---|---|
| Gene Symbols | Microarray | qPCR |
| Aurkb | 2.83 | 2.52 |
| Duox2 | −1.73 | −1.30 |
| Incenp | 2.33 | 1.85 |
| Pomc | −1.50 | −1.05 |
| Top2a | 3.27 | 3.44 |
Data are presented as mean fold changes in relative mRNA expression from control (n = 5 per treatment).
significantly altered in microarrays.
significantly altered in qPCR (p < 0.05).